Vima Therapeutics develops small-molecule therapies targeting G protein-coupled receptors (GPCRs) to treat neurological and psychiatric disorders.
Investors 1
Mentions in press and media 2
| Date | Title | Description |
| 30.05.2025 | Vima Therapeutics Raises $60M in Series A Funding | Vima Therapeutics, a Cambridge, MA-based clinical-stage biotechnology company, raised $60M in Series A funding.
The round was led by Atlas Venture, with participation from Access Industries and Canaan.
The company intends to use the funds t... |
| - | Vima Therapeutics | “There are over 1 million people with dystonia and related movement disorders in the US and over 100,000 people with isolated dystonia.” |
Reviews 0
